ABOUT
Eye conditions on the rise
Reality & numbers
2.2 billion people suffer from vision impairments of which 50% could be prevented or cured according to the World Health Organization. This number is growing due to our ageing populations and modern lifestyles.
Current testing standards are not fit for the 21st century. They require stationary and resource-intense workflows and often produce limited insights. This leads to bottlenecks in clinics and limited patient access to eye testing & adequate treatment.
ABOUT
Our mission
@Perivision
We want to change that and make eye testing & care accessible to everyone - everywhere. For this, PeriVision combines artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to test and understand visual function.
2017
1st peer-reviewed publication on AI-based fast perimetry
2018
Clinical study to validate AI-based fast-perimetry algorithm
2020
Clinical study on VR-based perimetry concluded
2021
Winning EIT Health Wild Card accelerator
2022
PeriVision SA incorporated & patents granted
2023
To be completed by something
2024
FDA registration of VisionOne platform
Our investors
INATEC AG
Our story
2017
1st peer-reviewed publication on AI-based fast perimetry
2018
Clinical study to validate AI-based fast-perimetry algorithm
2020
Clinical study on VR-based perimetry concluded
2021
Winning EIT Health Wild Card accelerator
2022
PeriVision SA incorporated & patents granted
2023
PeriVision USA incorporated & US clinical study
2024
FDA registration of VisionOne™ platform
Founders, board & management
Patrick Kessel
Co-founder, CEO & board member
Strategy consultant-turned-entrepreneur with a passion for healthcare innovation
Patrick Kessel holds a B.A. in Business Administration from the University of St. Gallen (HSG), including an exchange semester at Singapore Management University (SMU), and a MSc. in Political Science (Distinction) from the London School of Economics & Political Science (LSE). He is also a certified Scrum Master. Prior to joining PeriVision, he advised medtech, biopharma and insurance clients on business development, go-to-market strategy, digitization and operations optimization at the Boston Consulting Group (BCG). While at BCG, he initiated the firm’s tech startup support program “BCG Startup Unlock” to provide pro-bono strategy consulting to Swiss technology startups.
Dr. Serife Kucur Ergunay
Co-founder, CTO & board member
Award-winning AI researcher pushing the boundaries of vision care
Dr. Serife Kucur Ergunay holds a BSc. in Telecommunication Engineering from Istanbul Technical University, a MSc. in Information & Communication Technologies from École polytechnique fédérale de Lausanne (EPFL) where she obtained an EPFL Excellence Scholarship for Master Studies. She then obtained a PhD. in Biomedical Engineering from the ARTORG Center for Biomedical Engineering at the University of Bern. During more than six years of PhD. and post-doctoral research, she focused on applying AI to ophthalmology and perimetry data. For her translational research she has been granted a BRIDGE proof-of-concept grant by the Swiss National Science Foundation (SNCF). She has published multiple journal articles with leading clinicians and perimetry experts and presented her innovations at high-caliber scientific conferences such as the annual meetings of the Association for Research in Vision and Ophthalmology (ARVO) and the International Perimetry Society (PIS).
Prof. Dr. Raphael Sznitman
Co-founder & board member
Professor and serial entrepreneur at the intersection of AI and medicine
Prof. Dr. Raphael Sznitman holds a BSc. in Cognitive Systems in Computational Intelligence from the University of British Columbia and a MSc. and PhD. in Computer Science from John Hopkins University. He was a post-doctoral researcher at École polytechnique fédérale de Lausanne and is currently serving as Director of the ARTORG Center for Biomedical Engineering Research and the Center for AI in Medicine at the University of Bern. He has more than fifteen years of experience in AI solutions in health care and ophthalmology. He is also a co-founder and scientific advisor for RetinAI Medical AG, a Swiss AI and ophthalmology startup.
Kevin Gillmann
Chief Medical Officer
Ophthalmologist & glaucoma specialist with international clinical & research experience across the UK, US and Switzerland and 50+ peer-reviewed publications
Kevin Gillmann graduated from Newcastle University Medical School and earned his MD on Minimally-Invasive Glaucoma Surgery from the University of Lausanne. He also holds an MBA with Distinction from the University of London, a PhD from Kingston University, a post-graduate certificate in Media & Medicine from Harvard Medical School, and a Master of Architecture from the University of Paris LaVillette. His expertise spans across Europe and the United States, where he has held key positions, including Honorary Fellow at Moorfields Eye Hospital and Medical Director at Genève Ophtalmologie. With over 50 peer-reviewed publications and 850 citations, he is the editor of Elsevier’s glaucoma textbook «The Science of Glaucoma Management», and is a lecturer at the University of London.
MD. PhD. MBBS. MBA. FEBO. MCMI. MArch. PgCert
Dr. Ernest Cavin
Board member
Seasoned C-Level executive and experienced independent board director, leveraging his global business acumen in the ophthalmology sector to drive technological and healthcare advancements.
Ernest Cavin holds a BSc in Microelectronics/Micromechanics from the Bern University of Applied Sciences, an MBA from City University Seattle (WA), and a PhD in Business Administration from Argosy University (IL). He is currently the Vice President of International Sales at Ziemer Ophthalmology and has previously held the positions of CEO & President at Haag-Streit USA and Reliance Medical Products, renowned manufacturers of ophthalmic devices. In addition, he has contributed as a board member at Comlab, a company at the forefront of high-frequency technology and digital communication systems for trains. Ernest Cavin also serves on the board of Clovernook, a non-profit organization dedicated to assisting the blind and visually impaired. His commitment to advancing medical technology and healthcare extends to his past role on the panel committee of Glaucoma 360, the oldest and most experienced non-profit institution in America focused on curing glaucoma and restoring vision through groundbreaking research.
Walter Inäbnit
Investor & board observer
Eye care entrepreneur with decades of experience as former owner & chairman of leading Swiss ophthalmic device manufacturer Haag-Streit
Walter Inäbnit joined Haag-Streit in 1988 and was the instrumental force behind the company's global expansion and success based on innovation and high quality, before it was sold to SMI-listed Metall Zug Group in 2017. He is a highly respected figure in the ophthalmic industry and serves on various boards. He shares PeriVision’s ambition to advance eye care: “Bringing innovation into ophthalmology to improve clinical practice and patient care has been the work of my life at Haag-Streit. PeriVision shares the same vision. They want to make eye care much more accessible to patients and the lives of eye doctors easier."
Advisors
Prof. Dr. Jan Unterlauft
Clinical advisor
.png)
Eric Evans
Business advisor
Prof. Dr. Robert Weinreb
Clinical advisor
Dr. Timon Heinis
Technical advisor
Mark Lesselroth
Business advisor
Dr. Bobby Tang
Clinical advisor
ABOUT US
Our mission
2.2 billion people suffer from vision impairments of which 50% could be prevented or cured according to the World Health Organization. This number is growing due to our ageing populations and modern lifestyles.
Current testing mechanisms are not fit for the 21st century. They run on bulky devices, require stationary and expensive workflows and often produce limited insights.
At Perivision, we combine artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to understand visual function. Our systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.